menu
    • menu
    [{"orgOrder":0,"company":"Seraxis","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Series C Financing","leadProduct":"SR-01","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Seraxis","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Seraxis \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Seraxis \/ Eli Lilly"},{"orgOrder":0,"company":"Seraxis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SR-02","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Seraxis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seraxis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Seraxis \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Seraxis

    Menu

    Seraxis

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Seraxis

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            Seraxis

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SR-02

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of the Safety and Efficacy of Pancreatic Endocrine Cell Clusters Implanted Into the Omentum of Type 1 ...

                            Details : SR-02 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Diabetes Mellitus, Type 1.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 21, 2024

                            Lead Product(s) : SR-02

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Seraxis

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            Seraxis

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SR-01

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : Eli Lilly

                            Deal Size : $40.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Seraxis Announced Closing of $40M Series C Financing Round

                            Details : Proceeds from the financing will primarily be used to complete the preclinical testing of SR-01, Seraxis’ lead cell therapy treatment for insulin-dependent diabetes and initiate first-in-human clinical trials.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            February 09, 2021

                            Lead Product(s) : SR-01

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : Eli Lilly

                            Deal Size : $40.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth